These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 16517537

  • 1. Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
    Ruud E, Holmstrøm H, de Lange C, Natvig S, Albertsen BK, Wesenberg F.
    Pediatr Hematol Oncol; 2006; 23(3):207-16. PubMed ID: 16517537
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
    Castaman G, Rodeghiero F.
    Haematologica; 1993; 78(6 Suppl 2):57-60. PubMed ID: 8039761
    [Abstract] [Full Text] [Related]

  • 4. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
    Mall V, Thomas KB, Sauter S, Niemeyer CM, Sutor AH.
    Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
    [Abstract] [Full Text] [Related]

  • 5. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
    Mitchell LG, Andrew M, Hanna K, Abshire T, Halton J, Anderson R, Cherrick I, Desai S, Mahoney D, McCuster P, Wu J, Dahl G, Chait P, de Veber G, Lee KJ, Mikulis D, Ginsberg J, Way C, Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase Group (PARKAA).
    Cancer; 2003 Jan 15; 97(2):508-16. PubMed ID: 12518376
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
    Appel IM, Hop WC, Pieters R.
    Blood Coagul Fibrinolysis; 2006 Mar 15; 17(2):139-46. PubMed ID: 16479196
    [Abstract] [Full Text] [Related]

  • 10. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS, Kham SK, Ariffin H, Lin HP, Quah TC, Yeoh AE.
    Pediatr Blood Cancer; 2006 Sep 15; 47(3):299-304. PubMed ID: 16302217
    [Abstract] [Full Text] [Related]

  • 11. Low rate of severe venous thromboses in children with ALL treatment according to COALL-92 and -97 protocol.
    Mauz-Körholz C, Nürnberger W, Irsfeld H, Körholz D, Göbel U.
    Klin Padiatr; 1999 Sep 15; 211(4):215-7. PubMed ID: 10472553
    [Abstract] [Full Text] [Related]

  • 12. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
    Cohen H, Bielorai B, Harats D, Toren A, Pinhas-Hamiel O.
    Pediatr Blood Cancer; 2010 May 15; 54(5):703-6. PubMed ID: 20063421
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
    Hunault-Berger M, Chevallier P, Delain M, Bulabois CE, Bologna S, Bernard M, Lafon I, Cornillon J, Maakaroun A, Tizon A, Padrazzi B, Ifrah N, Gruel Y, GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang).
    Haematologica; 2008 Oct 15; 93(10):1488-94. PubMed ID: 18728028
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Changes in blood coagulation in treatment with ALL-BFM-90 and NHL-BFM-90 protocols].
    Sutor AH, Niemeyer C, Sauter S, Witt I, Kaufmehl K, Rombach A, Brandis M, Riehm H.
    Klin Padiatr; 1992 Oct 15; 204(4):264-73. PubMed ID: 1518263
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
    Boos J.
    Int J Clin Pharmacol Ther; 1997 Mar 15; 35(3):96-8. PubMed ID: 9088996
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.